The listed company Atrys Health has acquired the Valencian company Initia Oncology
Livingstone’s HealthCare team has advised the shareholders of Initia Oncology on the sale of 100% of their stake in the company, and a majority stake in its research unit, Initia Research.
Initia is Valencia based company, with a track record of more than eleven years in the provision of medical oncology services, and its professionals have extensive experience in the treatment of solid tumors. Initia is a national and international reference in the field of oncological medicine and cancer research and specializes in medical oncology through the most modern therapies.
Initia’s experience is based on excellence in the treatment of its patients and in cutting-edge research. To this end, it has a solid team of health professionals with extensive experience and high international prestige.
Atrys Health is a multinational medical company dedicated to preventive and precision medicine, and a leader in excellence of both diagnosis and treatment. The focus of Atrys Health is the individualized therapy of patients, through technological innovation. Atrys team is composed by more than 2,500 professionals, 90% of whom are healthcare professionals, of multiple nationalities and different specialties.
As part of its expansion plan, Atrys Health recently acquired Bienzobas, a company specialized in Medical Oncology, and continues to expand this line of business with the acquisition of Initia Oncología. Atrys Health is currently listed on the main market of the Madrid Stock Exchange since February 2022.
Carlos Fernández-Martos, partner at Initia said: “We are very pleased to have been able to rely on Livingstone’s professional service in the sale of our company. Their extensive experience in this type of process has been crucial for the successful completion of the transaction and for the negotiation of the closing conditions.
Andrés Poveda, partner at Initia says: “We hope that, with the integration into Atrys, Initia will continue to grow, develop its research activity and, above all, continue to provide its patients with the best service and treatment.
Eleuterio Abad, partner at Livingstone Partners comments: “It has been a very satisfying experience for Livingstone to assist in the integration of two companies such as Atrys and Initia, both of which are pursuing excellence in research and medical treatment of oncological diseases. We are confident that this transaction will enhance this excellence, which will undoubtedly benefit society.
This deal by Livingstone’s Healthcare team joins a long list of successful transactions in this sector, including Magnum’s acquisition of Apices, the sale of San Onofre Hospitales to Ita, and the sale of Therapy Partner Solutions to Lee Equity.
